| Recent developments with immunotherapy for hepatocellular carcinoma |
22 |
| Stem cell therapies for wound healing |
22 |
| Gene therapy for inherited retinal and optic nerve degenerations |
19 |
| A comprehensive review of hormonal and biological therapies for endometriosis: latest developments |
17 |
| Diabetic retinopathy: a complex pathophysiology requiring novel therapeutic strategies |
17 |
| Expert opinion on the use of biological therapy in non-infectious uveitis |
15 |
| Dental stem cells in tooth regeneration and repair in the future |
15 |
| B cell maturation antigen (BCMA)-based immunotherapy for multiple myeloma |
15 |
| Complement inhibition as a therapeutic strategy in retinal disorders |
14 |
| Anti-IL17 therapies for psoriasis |
14 |
| Results and challenges of immune checkpoint inhibitors in colorectal cancer |
13 |
| Secukinumab in moderate-to-severe plaque psoriasis: a multi-center, retrospective, real-life study up to 52 weeks observation |
12 |
| Monoclonal antibodies for treating osteoporosis |
12 |
| Effectiveness of omalizumab in adolescent and adult patients with chronic idiopathic/spontaneous urticaria: a systematic review of real-world' evidence |
12 |
| Effectiveness and safety of secukinumab in Italian patients with psoriasis: an 84 week, multicenter, retrospective real-world study |
11 |
| Ipilimumab in combination with nivolumab for the treatment of renal cell carcinoma |
11 |
| A vaccine against Alzheimer's disease: anything left but faith? |
11 |
| An overview of the efficacy and safety of systemic treatments for psoriasis in the elderly |
10 |
| Consumption of -glucans to spice up T cell treatment of tumors: a review |
10 |
| Development of new agents for peripheral T-cell lymphoma |
10 |
| B cell depletion in the treatment of multiple sclerosis |
10 |
| Anti-IL-17 monoclonal antibodies for the treatment of ankylosing spondylitis |
10 |
| Advances with platelet rich plasma therapies for tendon regeneration |
10 |
| MCLA- a CLEC12AxCD3 bispecific antibody targeting a leukaemic stem cell antigen, induces T cell-mediated AML blast lysis |
9 |
| Advances in stem cell therapy for amyotrophic lateral sclerosis |
9 |
| The progress of AAV-mediated gene therapy in neuromuscular disorders |
9 |
| An update on gene therapy for lysosomal storage disorders |
9 |
| AAV gene delivery to the spinal cord: serotypes, methods, candidate diseases, and clinical trials |
9 |
| Immunotherapy alone or chemo-immunotherapy as front-line treatment for advanced non-small cell lung cancer |
9 |
| CD38 as an immunotherapeutic target in multiple myeloma |
9 |
| Anti-interleukin-12 and anti-interleukin-23 agents in Crohn's disease |
9 |
| Biosimilars for the treatment of psoriasis |
9 |
| Repairing the corneal epithelium using limbal stem cells or alternative cell-based therapies |
8 |
| Inflammatory cytokines: from discoveries to therapies in IBD |
8 |
| Smoking reduces the efficacy of belimumab in mucocutaneous lupus |
8 |
| Challenges in the management of HIV infection: update on the role of probiotic supplementation as a possible complementary therapeutic strategy for cART treated people living with HIV/AIDS |
8 |
| Current and emerging biologic and small molecule therapies for atopic dermatitis |
8 |
| Lessons learned from lung and liver in-vivo gene therapy: implications for the future |
8 |
| Engineered oncolytic viruses to treat melanoma: where are we now and what comes next? |
8 |
| Respiratory syncytial virus vaccine: where are we now and what comes next? |
8 |
| The potential of solanezumab and gantenerumab to prevent Alzheimer's disease in people with inherited mutations that cause its early onset |
8 |
| Maintaining consistent quality and clinical performance of biopharmaceuticals |
8 |
| Oncolytic adenoviruses: a game changer approach in the battle between cancer and the immune system. |
8 |
| Immune checkpoint inhibition for the treatment of mesothelioma |
7 |
| An update on therapies for the treatment of diabetes-induced osteoporosis |
7 |
| Combining cell and gene therapy to advance cardiac regeneration |
7 |
| Interchangeability of biosimilar and biological reference product: updated regulatory positions and pre- and post-marketing evidence |
7 |
| Poxvirus oncolytic virotherapy |
7 |
| Stargardt macular dystrophy and evolving therapies |
7 |
| Monoclonal antibodies for the prevention of migraine |
7 |
